by Corina Milic | Aug 25, 2021
The report provides market intelligence on hepatitis C (HCV) diagnostics and drugs in low- and middle-income countries to help guide elimination of the disease. It also covers preliminary insights into the hepatitis B (HBV) market. We are pleased to release the second...
by Corina Milic | Aug 16, 2021
CHAI is pleased to share news today from MedAccess of measures to increase access to a patient-friendly preventative therapy for tuberculosis (TB). The volume guarantee agreement between MedAccess and Macleods Pharmaceuticals, in partnership with CHAI and...
by Corina Milic | Aug 12, 2021
Our monthly check-in with staff from around the world. Learn more about the people who work at CHAI. Please tell us a bit about your background and what brought you to CHAI. I grew up in France and studied veterinary medicine there. I have always been fascinated by...
by Corina Milic | Jul 27, 2021
Hepatitis B (HBV) is an incurable liver infection that can lead to severe health consequences including liver failure and liver cancer. It is a silent killer – most people do not experience any symptoms when they get infected and children in particular are less able...
by Corina Milic | Jul 25, 2021
Unitaid and the Clinton Health Access Initiative, Inc. (CHAI) announce pricing agreement with pharmaceutical company Hetero Labs LTD to make available generic version of best-in-class second-line therapy for people living with HIV. July 26, 2021 – Unitaid and CHAI...
